Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica C Hassel

Showing results (171-180 of 272) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIvelina Spassova, Selma Ugurel, Patrick Terheyden, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Annals of the Rheumatic Diseases|August 3, 2022
Distinct immune-effector and metabolic profile of CD8<sup>+</sup> T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitorsKarolina Benesova, Franziska Viktoria Kraus, Rui A Carvalho, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 1, 2026
Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centersNina Flatt, Corinna Kochanek, Yenny Angela, et al.
Melanoma Research|November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNISKatharina C Kähler, Dirk Debus, Gaston Schley, et al.
Oncoimmunology|April 28, 2022
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)Jessica C Hassel, Timo E Schank, Heiko Smetak, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II studySandra P D'Angelo, Celeste Lebbé, Laurent Mortier, et al.
Journal for Immunotherapy of Cancer|January 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanomaRobin Reschke, Petra Budde, Hans-Dieter Zucht, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutionsThomas K Eigentler, Max Schlaak, Jessica C Hassel, et al.
JAAD International|June 17, 2024
Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelBarbara Meier-Schiesser, Christine Zecha, Sarah Zierold, et al.
Pageof 28

Showing results (171-180 of 272) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIvelina Spassova, Selma Ugurel, Patrick Terheyden, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Annals of the Rheumatic Diseases|August 3, 2022
Distinct immune-effector and metabolic profile of CD8<sup>+</sup> T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitorsKarolina Benesova, Franziska Viktoria Kraus, Rui A Carvalho, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 1, 2026
Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centersNina Flatt, Corinna Kochanek, Yenny Angela, et al.
Melanoma Research|November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNISKatharina C Kähler, Dirk Debus, Gaston Schley, et al.
Oncoimmunology|April 28, 2022
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)Jessica C Hassel, Timo E Schank, Heiko Smetak, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II studySandra P D'Angelo, Celeste Lebbé, Laurent Mortier, et al.
Journal for Immunotherapy of Cancer|January 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanomaRobin Reschke, Petra Budde, Hans-Dieter Zucht, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutionsThomas K Eigentler, Max Schlaak, Jessica C Hassel, et al.
JAAD International|June 17, 2024
Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelBarbara Meier-Schiesser, Christine Zecha, Sarah Zierold, et al.
Pageof 28